id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2020-D-1137-0110,FDA,FDA-2020-D-1137,Policy for Certain REMS Requirements During the Tocilizumab Shortage Related to the COVID-19 Public Health Emergency,Other,Guidance,2021-12-13T05:00:00Z,2021,12,2021-12-13T05:00:00Z,,2024-11-12T23:35:10Z,,1,0,0900006484ec1526
FDA-2020-D-1137-0103,FDA,FDA-2020-D-1137,Guidance Documents Related to Coronavirus Disease 2019; Availability,Notice,Notice of Availability,2021-07-23T04:00:00Z,2021,7,2021-07-23T04:00:00Z,,2021-07-23T15:15:46Z,2021-15649,0,0,0900006484c0aa4d
FDA-2020-D-1137-0099,FDA,FDA-2020-D-1137,Emergency Use Authorization for  Vaccines to Prevent COVID-19,Other,Guidance,2021-06-04T04:00:00Z,2021,6,2021-06-04T04:00:00Z,,2022-04-25T03:46:42Z,,0,0,0900006484b56371
FDA-2020-D-1137-0098,FDA,FDA-2020-D-1137,Emergency Use Authorization for  Vaccines to Prevent COVID-19,Other,Guidance,2021-06-04T04:00:00Z,2021,6,2021-06-04T04:00:00Z,,2022-04-25T03:46:23Z,,0,0,0900006484b5633e
FDA-2020-D-1137-0090,FDA,FDA-2020-D-1137,Guidance Documents Related to  Coronavirus Disease 2019; Availability,Notice,Notice of Availability,2021-04-26T04:00:00Z,2021,4,2021-04-26T04:00:00Z,,2024-11-06T23:46:14Z,86 FR 21744,1,0,0900006484ab6bda
FDA-2020-D-1137-0086,FDA,FDA-2020-D-1137,Good Manufacturing Practice Considerations for Responding to COVID-19 Infection in Employees in Drug and Biological Products Manufacturing - Guidance for Industry - June 2020,Supporting & Related Material,Background Material,2021-02-22T05:00:00Z,2021,2,,,2021-02-22T16:33:35Z,,0,0,0900006484a46b7c
FDA-2020-D-1137-0087,FDA,FDA-2020-D-1137,TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes,Supporting & Related Material,Background Material,2021-02-22T05:00:00Z,2021,2,,,2021-02-22T20:34:48Z,,0,0,0900006484a46e11
FDA-2020-D-1137-0085,FDA,FDA-2020-D-1137,Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro,Supporting & Related Material,Background Material,2021-02-22T05:00:00Z,2021,2,,,2021-02-22T16:30:39Z,,0,0,0900006484a46b58
FDA-2020-D-1137-0083,FDA,FDA-2020-D-1137,"Manufacturing Considerations for Licensed and Investigational Cellular and Gene Therapy Products During COVID-19 Public Health Emergency
Guidance for Industry",Other,Guidance,2021-02-09T05:00:00Z,2021,2,2021-02-09T05:00:00Z,2023-05-12T03:59:59Z,2023-05-11T20:53:06Z,,0,0,0900006484a23d3a